Project Grant R21CA286283
Award Date
7/4/24
Completion Date
6/30/26
Dollars Obligated
$402K
Federal Agency
National Cancer Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of a multiparametric endoscopic ultrasound (MPEUS) imaging system to improve pancreatic cancer screening and characterization. The $263,086 award to the Sloan-Kettering Institute for Cancer Research will fund the implementation of real-time MPEUS, which uses B-mode, ultrasensitive microvessel imaging, shear-wave elastography, and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Oncotab, Inc. to develop an optimized targeted radiotherapy approach for treating pancreatic ductal adenocarcinoma (PDAC). The project aims to conduct a structured design of experiments to evaluate the efficacy of a humanized tumor-associated antibody (HTAB004) and a tandem single-chain variable fragment (scFv) construct as targeting agents, labeled with alpha and beta...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is funding research to investigate the role of the cancer-specific Tn antigen in pancreatic ductal adenocarcinoma (PDAC) tumor progression and metastasis. The $1,130,538 grant, awarded on December 20, 2024, will support a 5-year research project at the University of Louisville. The key objectives are to: 1) determine the mechanisms by which the Tn antigen enhances PDAC tumor growth and...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $622,984 to the University of California, Los Angeles (UCLA) to conduct a systems metabolic approach for multi-scale pancreatic cancer phenotyping. The award aims to characterize the pancreatic cancer microenvironment and tumor-stroma interface at the cellular and tissue levels, enabling assessment of glycolytic and inflammatory characteristics of...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to improve early detection and screening for pancreatic cancer. The key products and services to be delivered include: Development of a highly specific blood-based early detection test for pancreatic cancer, called "PancSeek", to improve screening for high-risk populations. Creation of an integrated risk model,...
This $399,829 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research by The Washington University in St. Louis to validate an S1PR1-targeted PET imaging approach that can quantitatively measure early response to antibody-drug conjugate (ADC) therapies in gastric cancer models. The research aims to correlate tumor S1PR1 levels, HER2 availability, and genetic alterations with gastric tumor response to ADCs. Through...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will develop novel methods to image two different PET radiotracers back-to-back in a single imaging session, using the PennPET Explorer whole-body PET scanner. The $597,766 award, spanning from June 1, 2025 to May 31, 2030, will focus on two research aims: Develop protocols to image fluoroglutamine, a radiotracer of glutamine metabolism, in combination with FDG in breast cancer...
The National Cancer Institute (NCI) awarded a $431,970 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Albert Einstein College of Medicine to characterize and test a novel method for in vivo monitoring of Listeria bacteria using 18F-fluorodeoxyglucose (FDG) and positron emission tomography (PET) scans. The goal is to develop this tool to visualize the distribution of Listeria bacteria in tumors and metastases, which could help determine the success of Listeria-based...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,960,529 to the University of California, Los Angeles (UCLA) to conduct research on the causes and consequences of adenosine signaling in pancreatic cancer. The key objectives are to: Extensively evaluate pre- and post-treatment patient specimens from a clinical trial to define the impact of CD73 inhibition on tumor adenosine metabolism, signaling, and immunosuppression. This will...
This Project Grant award of $666,670 from the National Cancer Institute (NCI), under the CFDA 93.394 Cancer Detection and Diagnosis Research program, aims to develop innovative scan protocols that combine long axial field-of-view Positron Emission Tomography (PET) and spectral Computed Tomography (CT) imaging to enhance quantification capabilities in oncology. The key goals are to: 1) Develop spectral CT protocols and processing pipelines to generate dynamic iodine maps and perfusion data; 2)...